Skip to main content

Table 1 Characteristics of studies included in the analysis

From: Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis

Author, year Study type Duration of treatment, weeks Treatment Number of patients Characteristics of patients
Mean age (years) Gender (% female) Mean BMI (kg/m2) Diabetes duration (years)
Berhanu et al. [13] randomized placebo-controlled 20 PIO + INS 110 52.9 56.4 30.7 7.7
PLB + INS 112 52.5 58.9 31.8 8.5
Belfort et al. [14] randomized placebo-controlled 24 PIO 45 mg 26 51 46.1 33.5 NA
PLB 21 51 70 32.9 NA
Mattoo et al. [15] randomized, double-blind, prospective, multicenter, placebo-controlled 25 PIO 30 mg + INS 142 58.9 56.7 NA NA
PLB + INS 147
DeFronzo et al. [16] randomized, double-blind, placebo-controlled 125 PIO initially 30 mg after month 45 mg 303 53 42 33 Patients with IGT and IFGT
PLB 299 51.5 42 34.5
DeFronzo et al. [17] randomized, double-blind, placebo-controlled 125 PIO initially 30 mg after month 45 mg 213 53.9 44 33.4 Patients with IGT and IFGT
PLB 228 52.5 42 34.4
Rosenstock et al. [18] randomised, placebo-controlled study 16 PIO 15 mg + INS 191 56.9 53.9 33.2 NA
PIO 30 mg + INS 188 57.5 49.5 34.3 NA
PLB + INS 187 56.7 54.5 33.2 NA
Davidson et al. [19] randomized, double-blind, multicenter 24 PIO 30 mg + INS 345 NA NA 33.2 12.9
PIO 45 mg + INS 345
Goldberg et al. [3] randomized, double-blind, prospective, multicenter 24 PIO 30 mg for 12 weeks, then 45 mg for 12 weeks 369 55.9 46.1 33.7 3.9
ROSI 4 mg for 12 weeks, then 8 mg for 12 weeks 366 56.3 45.1 32.6 4.0
Xu et al. [20] randomized, multicenter 48 EXE 149 NA NA NA NA
INS 149
PIO 118
Bolli et al. [12] multicentre, randomized, active-controlled 52 PIO 30 mg + MET 1500 mg 281 57 35.9 32.1 6.4
VIL 100 mg + MET 1500 mg 295 56.3 38.3 32.2 6.4
Gerber et al. [21] randomized, multicenter 20 PIO 30 mg 76 NA NA NA NA
PIO 30 mg for 12 weeks then 45 mg for 8 weeks 74
PIO 45 mg 84
Panikar et al. [22] randomised 24 PIO 7.5 mg 77 58.2 47.4 27.6 < 2
PIO 15 mg 80 56.6 43.7 26.6
PIO 45 mg 80 53.7 40 25.8
Kodama et al. [23] prospective, randomized, open-label, comparator-controlled 16 PIO 32 68.4 28.1 25.2 NA
GLI 21 66.7 19 24.7
Shah et al. [24] randomised 12–16 INS + PIO 45 mg 12 58 16 36.7 NA
INS + PLB 13
Yoshii et al. [25] prospective, randomized, open-label, multicenter 96 with PIO 234 69.0 36.8 24.2 11.1
without PIO 247 68.9 34.0 24.3 11.5